Baudax Bio Announces Dosing of First Cohort in First-in-Man, Phase I Clinical Study Evaluating BX2000
June 01, 2022 08:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for acute care settings, today announced that the first cohort...
Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference
May 18, 2022 08:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood,...
Baudax Bio Announces $2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
May 17, 2022 19:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that...
Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders
May 05, 2022 17:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that...
Baudax Bio Reports First Quarter 2022 Financial Results and Business Highlights
May 04, 2022 17:00 ET
|
Baudax Bio, Inc.
ANJESO® Net Product Revenue Up 113% Compared to Same Period in Prior Year; Sixth Consecutive Quarter of Demand Growth First Cohort Dosed in Pediatric ANJESO Surgical Study Management to Host...
Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
May 02, 2022 16:05 ET
|
Baudax Bio, Inc.
MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report...
Baudax Bio to Present at NobleCon18 Investor Conference
April 13, 2022 08:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., April 13, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...
Baudax Bio Reports 2021 Fourth Quarter and Annual Financial Results
March 16, 2022 08:00 ET
|
Baudax Bio, Inc.
ANJESO End User Demand and Revenue Increases Four Quarters In A Row Neuromuscular Blocking Agents Advancing MALVERN, Pa., March 16, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the...
Baudax Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference
March 10, 2022 07:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on commercializing and developing innovative products for acute care settings,...
Baudax Bio Initiates Phase IV Clinical Trial Evaluating ANJESO® in Pediatric Patients Following Surgery
March 08, 2022 08:00 ET
|
Baudax Bio, Inc.
MALVERN, Pa., March 08, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today...